UNSPSC 51285501: Clazuril

This classification denotes an antiparasitic agent with the molecular formula C17H10Cl2N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O8W0R05772, chemically known as benzeneacetonitrile, 2-chloro-alpha-(4-chlorophenyl)-4-(4,5-dihydro-3,5-dioxo-1,2,4-triazin-2(3h)-yl)- but generally known as clazuril, which bears US NIH Compound Identifier 58901. European Medicines Agency schedules Clazuril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06645MIG.

UNSPSC 51285501 Clazuril, a Commodity code, does not align with the state and local contract opportunities currently posted under it. The code nominally identifies clazuril, an antiprotozoal veterinary pharmaceutical, yet the recent solicitations in the source block procure naloxone, safe drug deactivation systems, medical and first aid supplies, and generic pharmaceuticals for human use — none of which are clazuril or veterinary products. The mismatch suggests either a data-tagging error in the source system or that this code has been repurposed to capture broader pharmaceutical procurement. State and local issuers—including Seminole County, Florida; the City of Tampa; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—are sourcing emergency medical supplies, opioid-reversal agents, and generic human pharmaceuticals through competitive bidding, RFIs, and cooperative purchasing vehicles, but none of these activities map to the code's stated pharmaceutical scope.

Recent opportunities show activity across Florida, Texas, Minnesota, and Oregon. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health support. The City of Tampa released an IFB for medical and first aid supplies for the Fire Department Rescue Division (Solicitation 26P00145, due March 13, 2026, estimated value $700,000, with set-aside for Small Local Business Enterprises). The Texas HHS Commission posted an RFI (HHS0017013, April 3, 2026) to explore direct-to-manufacturer pharmacy programs. MMCAP issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. Firms considering this code should verify whether their pharmaceutical product lines—particularly clazuril or veterinary pharmaceuticals—actually match current state and local demand, as the available opportunities do not reflect the code's nominal scope.